Anders Sönnerborg to Drug Resistance, Viral
This is a "connection" page, showing publications Anders Sönnerborg has written about Drug Resistance, Viral.
Connection Strength
2.501
-
A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort. BMC Infect Dis. 2019 Jul 01; 19(1):569.
Score: 0.481
-
Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing. Sci Rep. 2018 05 15; 8(1):7556.
Score: 0.445
-
Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. AIDS. 2018 04 24; 32(7):877-884.
Score: 0.443
-
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS One. 2017; 12(6):e0178942.
Score: 0.417
-
Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. J Med Virol. 2009 Jan; 81(1):1-8.
Score: 0.233
-
MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors. Viruses. 2019 08 30; 11(9).
Score: 0.122
-
Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2018 02 20; 32(4):469-476.
Score: 0.110
-
Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. AIDS. 2018 Jan 14; 32(2):161-169.
Score: 0.109
-
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014 Jul 21; 14:407.
Score: 0.085
-
Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. J Antimicrob Chemother. 2018 10 01; 73(10):2721-2728.
Score: 0.029
-
Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. Int J Antimicrob Agents. 2018 May; 51(5):733-738.
Score: 0.027